FCGR3A
Low affinity immunoglobulin gamma Fc region receptor III-A
As of the edition of 20 October 2026, FCGR3A (low affinity immunoglobulin gamma Fc region receptor III-A, UniProt P08637) has 7 drugs tested at it and 6 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08637
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 15
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Pregnancy and women's health; Urinary and reproductive; Hormones; Heart and blood vessels
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 6 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bemarituzumab | Stopped | Phase 3 | none listed |
| Acimtamig | Stopped | Phase 2 | none listed |
| Imgatuzumab | Stopped | Phase 2 | none listed |
| AFM24 | Stopped | Phase 2 | none listed |
| AFM28 | Stopped | Phase 1 | none listed |
| CC-96191 | Stopped | Phase 1 | none listed |
| RO7297089 | Status not established | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Undetermined | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Amgen | Route A |
| Bristol Myers Squibb | Route A |
| Affimed | Route A |
The other 3 companies at FCGR3A
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at FCGR3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.